Today: 23 November 2025
Subscribe
Browse Tag

weight loss

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Pops as White House Strikes Obesity-Drug Pricing Deal; New 20% Weight‑Loss Data Fuels Momentum — Today, November 6, 2025

Eli Lilly stock today: drivers, numbers, and what to watch for next. Key takeaways (Nov 6, 2025) Eli Lilly stock today: quote & range As of this afternoon, LLY traded near $935.89, up about 1.1%, with today’s range $916.37–$949.90 and a 52‑week range $624.00–$955.43 (values delayed up to 15 minutes). Reuters 1) The White House’s obesity‑drug deal: lower prices, broader access President Donald Trump announced deals with Eli Lilly and Novo Nordisk to reduce U.S. costs and expand coverage for in‑demand weight‑loss medicines. The plan includes Medicare coverage for obesity treatment, expected to carry $50 monthly copays for eligible beneficiaries,
6 November 2025
 ·  ·  ·  ·  ·  · 
Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Company Overview & Stock Snapshot Pfizer Inc. is one of the world’s largest pharmaceutical companies, known for household-name drugs and vaccines. Headquartered in New York, Pfizer manufactures treatments across vaccines, oncology, immunology, cardiology, and more. The company gained global prominence for its COVID-19 vaccine (Comirnaty) and antiviral pill (Paxlovid). However, with the pandemic’s tide receding, Pfizer’s stock (PFE) has faced significant challenges in 2023–2025. Shares that once traded above $50 during the vaccine rollout now hover in the mid-$20s reuters.com. At around $24–$25 per share, Pfizer’s market cap is about $138 billion stockanalysis.com – substantially smaller than several years ago
5 November 2025
 ·  ·  ·  ·  · 
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Once Sky-High Valuation Falters Amid Weight-Loss Drug Headwinds Just a year ago, Novo Nordisk – buoyed by the meteoric success of its weight-loss injection Wegovy – briefly eclipsed all other European companies in market value reuters.com. The Danish pharmaceutical giant enjoyed surging sales as Wegovy and its type-2 diabetes sibling Ozempic (both containing the GLP-1 agonist semaglutide) became global sensations, with millions seeking their dramatic weight-loss benefits. However, 2025 has seen a sharp reversal of fortune. A “slew of headwinds has shaken investor confidence” in Novo Nordisk’s once-dominant growth story stockanalysis.com. The company’s share price has plummeted nearly 50% year-to-date
5 November 2025
 ·  ·  ·  ·  · 
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Analyst outlook & forecast: Long-term, analysts model robust growth. For example, one financial model projects ~18% revenue CAGR: ~$3.3 billion in sales by 2028 and ~$261 million net income simplywall.st. Another estimate sees revenue rising from ~$2.35 B in 2025 to ~$3.34 B by 2027 tipranks.com, and free cash flow turning positive in 2025 simplywall.st. These forecasts assume continued momentum in weight-loss/metabolic services plus gains in new verticals. Yet many investors note the high valuation (HIMS trades near ~$45 with market cap in the billions) and regulatory/legal risks. Community “fair value” estimates vary widely (some as low as $41) due to uncertainty simplywall.st. Key
3 November 2025
 ·  ·  ·  ·  · 
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Stock Price and Recent Performance Pfizer’s stock has languished in 2025 despite a rising broader market. At ~$24.65, PFE is roughly flat since January and far below its 2021 peak (~$50) sharewise.com. In the past three years, the shares have tumbled about 50% as the company’s COVID-fueled revenue boom faded and investors braced for patent expirations sharewise.com. By mid-2025, Pfizer traded near multi-year lows (around $23), though it bounced off those lows in early October after positive news on earnings and policy. Notably, Pfizer’s stock surged ~15% at the end of Q3 (from ~$23.85 on Sept. 29 to ~$27.37 by
3 November 2025
 ·  ·  ·  ·  · 
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk’s $9B Shock Bid Snatches US Weight-Loss Biotech from Pfizer – Stocks React Big

Bidding War Ignites for Obesity Biotech Novo’s takeover push marks a sudden escalation in the weight-loss drug wars. The Danish company – maker of Wegovy and Ozempic – broke ranks on Oct. 30 by notifying Metsera’s board of its superior bid reuters.com. This move comes just days after the foundation coup at Novo (demanding faster U.S. growth) reuters.com, signaling a full-aggression strategy. Metsera confirmed the offer is “superior” to Pfizer’s, giving Pfizer four business days to respond ts2.tech. Pfizer CEO Albert Bourla has publicly talked up this obesity play, so Pfizer is not likely to concede easily. Unsurprisingly, Pfizer immediately
31 October 2025
 ·  ·  ·  ·  ·  ·  · 
Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Stock Price & Recent Performance Pfizer’s stock has been rangebound in the low-to-mid $20s for much of 2025. By late September, PFE traded around $23.60 – about 9% below its price a year earlier ts2.tech – as investors grappled with the end of Covid vaccine and treatment revenues. That all changed in early October. In the final trading week of September, Pfizer shares jumped ~15%, rallying from roughly $23.6 (Sept. 25) to about $27.2 by Oct. 1 ts2.tech. This dramatic move was largely driven by two key announcements (see below) and marked one of PFE’s strongest weekly gains in years.
30 October 2025
 ·  ·  ·  ·  · 
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Boardroom Shake-Up Spurs Investor Nerves Novo’s stock slide accelerated this week amid a dramatic boardroom conflict. On Oct. 21, the Novo Nordisk Foundation (the company’s controlling shareholder) announced it would remove chair Helge Lund and six other independent directors. A Reuters report noted that this “boardroom coup” came amid disagreement over strategy and a push for “a sharper focus on the key U.S. market to revive sales” reuters.com reuters.com. Former CEO Lars Rebien Sørensen is set to take over as chair for 2–3 years reuters.com. Trading reacted sharply. Novo’s Copenhagen-listed shares briefly plunged 6% on Oct. 17 when President Trump
22 October 2025
 ·  ·  ·  ·  · 
Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Menopause Launch Sparks Surge in HIMS Stock Hims & Hers’ expansion into menopause care was greeted with enthusiasm in the market. On October 15, the San Francisco–based telehealth provider announced it is now offering affordable treatment plans for women in perimenopause and menopause via its Hers platform businesswire.com businesswire.com. The move adds a new specialty to Hers, which already serves over 500,000 women subscribers businesswire.com. By connecting patients with providers trained in menopause care, Hims & Hers aims to fill a long-neglected gap in women’s health. “Women have been navigating an outdated healthcare system that wasn’t designed for them for
17 October 2025
 ·  ·  ·  ·  · 
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

NVO Stock Slides as Weight-Loss Hype Cools Novo Nordisk’s stock has been on a wild ride. After becoming Europe’s most valuable company in 2022–2023 on the back of its smash-hit obesity drug Wegovy, the Danish pharma giant has seen its fortunes reverse sharply in 2025. As of October 17, NVO shares trade in the mid-$50s – down nearly 50% from January levels reuters.com reuters.com and miles below the late-2024 peak (when Novo’s market cap neared $650 B) reuters.com reuters.com. What happened? In short, the once-unbounded GLP-1 weight-loss boom has hit reality. Several factors have converged to deflate Novo’s valuation. Competition has
17 October 2025
 ·  ·  ·  ·  ·  ·  ·  · 
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer (PFE) Stock Soars on Trump’s Drug-Price Pact and $7.3B Weight-Loss Deal

Stock Performance (Sep 2025) On Sept 30, 2025 Pfizer closed around $24.40 reuters.com. Over the past year PFE underperformed the pharma sector (latest 52-week range ~$20.91–30.43 reuters.com). Its trailing P/E is 12.64× reuters.com (ex. special items) and forward P/E ~7.7× reuters.com, compared to ~19× for J&J and ~12× for Merck (see table). Pfizer’s dividend yield (~7.2%) reuters.com is by far the highest in big pharma (JNJ ~2.9%, MRK ~4.1%). The stock rallied on strong earnings in early August s206.q4cdn.com reuters.com and on the Sept 30 Trump pricing news. Q2 2025 Financial Results and Corporate Updates Pfizer reported Q2 2025 revenue
30 September 2025
 ·  ·  ·  ·  ·  · 
Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

Hims & Hers Health Stock Skyrockets amid Weight-Loss Mania – But FDA Scrutiny Looms

“It’s never been more clear that we are delivering exactly what millions of people have been waiting for,” said HIMS CEO Andrew Dudum after Q2 results investors.hims.com. With analysts ranging from “Sell” to “Buy”, and social media buzzing, Hims & Hers remains one of 2025’s most talked-about healthcare stocks – its fortunes tightly tied to both the telehealth boom and regulatory oversight. Sources: Recent filings and press releases investors.hims.com investors.hims.com; Reuters and AP news on regulatory actions reuters.com reuters.com reuters.com; analyst reports and SEC filings quiverquant.com marketbeat.com; and HIMS-sponsored studies/news investors.hims.com fox10tv.com. (All figures as reported; analysis current as of
29 September 2025
 ·  ·  ·  ·  ·  · 
1 2
Go toTop